NASDAQ:PRPO - Precipio Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.54 -0.01 (-1.82 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$0.54
Today's Range$0.5011 - $0.55
52-Week Range$0.36 - $28.16
Volume1.48 million shs
Average Volume2.58 million shs
Market Capitalization$10.76 million
P/E RatioN/A
Dividend YieldN/A
Beta0.59

About Precipio (NASDAQ:PRPO)

Precipio logoPrecipio, Inc. provides platform to eradicate the problem of misdiagnosis within academic institutions. The company also delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Receive PRPO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRPO
CUSIPN/A
Phone203-787-7888

Debt

Debt-to-Equity Ratio0.22
Current Ratio0.14
Quick Ratio0.16

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.72 million
Price / Sales6.18
Cash FlowN/A
Price / CashN/A
Book Value$0.68 per share
Price / Book0.79

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-20,690,000.00
Net Margins-1,166.80%
Return on Equity-151.44%
Return on Assets-80.44%

Miscellaneous

Employees33
Outstanding Shares19,690,000

Precipio (NASDAQ:PRPO) Frequently Asked Questions

What is Precipio's stock symbol?

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

When did Precipio's stock split? How did Precipio's stock split work?

Precipio shares reverse split on the morning of Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

How were Precipio's earnings last quarter?

Precipio (NASDAQ:PRPO) announced its earnings results on Friday, August, 12th. The biotechnology company reported ($3.00) EPS for the quarter. The biotechnology company had revenue of $0.51 million for the quarter. Precipio had a negative return on equity of 151.44% and a negative net margin of 1,166.80%. View Precipio's Earnings History.

Who are some of Precipio's key competitors?

Who are Precipio's key executives?

Precipio's management team includes the folowing people:
  • Mr. Ilan Danieli, Founder, CEO & Pres
  • Mr. Carl R. Iberger, CFO & Sec.
  • Zaki Sabet, VP of Operations
  • Mr. Douglas Sites, VP of Sales
  • Mr. Stephen R. Miller, Chief Commercial Officer (Age 52)

Has Precipio been receiving favorable news coverage?

News headlines about PRPO stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Precipio earned a media sentiment score of 0.16 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.66 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Precipio's major shareholders?

Precipio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sabby Management LLC (3.88%). View Institutional Ownership Trends for Precipio.

Which major investors are buying Precipio stock?

PRPO stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Precipio.

How do I buy shares of Precipio?

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Precipio's stock price today?

One share of PRPO stock can currently be purchased for approximately $0.54.

How big of a company is Precipio?

Precipio has a market capitalization of $10.76 million and generates $1.72 million in revenue each year. Precipio employs 33 workers across the globe.

How can I contact Precipio?

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at 203-787-7888 or via email at [email protected]


MarketBeat Community Rating for Precipio (PRPO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  144
MarketBeat's community ratings are surveys of what our community members think about Precipio and other stocks. Vote "Outperform" if you believe PRPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRPO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Precipio (NASDAQ:PRPO) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/26/2016 forward)

Earnings

Precipio (NASDAQ:PRPO) Earnings History and Estimates Chart

Earnings by Quarter for Precipio (NASDAQ:PRPO)

Precipio (NASDAQ PRPO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/20/2017Q3 2017($1.22)$0.33 millionViewN/AView Earnings Details
8/21/2017Q2 2017($15.35)$0.26 millionViewN/AView Earnings Details
5/18/2017Q1 2017($2.10)$0.66 millionViewN/AView Earnings Details
11/14/2016Q3 2016($2.40)$0.46 millionViewN/AView Earnings Details
8/12/2016Q216($3.00)$0.51 millionViewListenView Earnings Details
5/23/2016Q116($3.00)$0.24 millionViewListenView Earnings Details
11/12/2015Q315($8.10)($5.40)$6.65 million$4.00 millionViewListenView Earnings Details
8/13/2015Q215($12.30)($9.00)$7.10 million$7.00 millionViewListenView Earnings Details
5/14/2015Q115($15.60)($10.80)$6.80 million$6.51 millionViewListenView Earnings Details
4/15/2015Q414($16.80)($23.10)$6.20 million$7.70 millionViewN/AView Earnings Details
10/30/2014($17.40)($18.30)$6.80 million$6.37 millionViewN/AView Earnings Details
8/6/2014Q2 2014($15.92)($17.12)$6.25 million$6.76 millionViewN/AView Earnings Details
5/7/2014($14.10)($18.00)$6.73 million$6.25 millionViewN/AView Earnings Details
3/12/2014($10.80)($1.50)$6.71 million$6.22 millionViewN/AView Earnings Details
11/6/2013Q3 2013($10.82)($21.63)$6.65 millionViewN/AView Earnings Details
8/6/20132Q13($0.90)($0.90)$7.96 million$7.31 millionViewN/AView Earnings Details
5/8/20131Q13($0.90)($1.20)$7.53 million$7.37 millionViewN/AView Earnings Details
3/13/20134Q12($0.90)($0.90)ViewN/AView Earnings Details
11/7/2012Q3 2012($10.82)($14.42)ViewN/AView Earnings Details
8/1/2012Q2 2012($3.61)($3.61)ViewN/AView Earnings Details
5/8/2012Q1 2012($7.21)($16.58)ViewN/AView Earnings Details
3/7/2012Q4 2011($7.21)$0.36ViewN/AView Earnings Details
11/9/2011Q3 2011($11.18)ViewN/AView Earnings Details
8/11/2011Q2 2011($10.82)($8.29)ViewN/AView Earnings Details
5/12/2011Q1 2011($5.05)ViewN/AView Earnings Details
3/10/2011Q4 2010($5.77)ViewN/AView Earnings Details
11/15/2010Q3 2010($6.49)ViewN/AView Earnings Details
8/12/2010Q2 2010($8.29)ViewN/AView Earnings Details
5/5/2010Q1 2010($2.52)ViewN/AView Earnings Details
2/24/2010Q4 2009$1.08ViewN/AView Earnings Details
11/5/2009Q3 2009($2.52)ViewN/AView Earnings Details
8/12/2009Q2 2009($5.41)ViewN/AView Earnings Details
5/13/2009Q1 2009($6.85)ViewN/AView Earnings Details
3/18/2009Q4 2008($1.44)ViewN/AView Earnings Details
10/29/2008Q3 2008($3.61)ViewN/AView Earnings Details
5/7/2008Q1 2008$0.72ViewN/AView Earnings Details
2/28/2008Q4 2007$2.52ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Precipio (NASDAQ:PRPO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Precipio (NASDAQ PRPO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.70%
Institutional Ownership Percentage: 11.41%
Insider Trading History for Precipio (NASDAQ:PRPO)
Institutional Ownership by Quarter for Precipio (NASDAQ:PRPO)

Precipio (NASDAQ PRPO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/22/2014Leroy C KoppMajor ShareholderSell413,050$3.70$1,528,285.00View SEC Filing  
10/2/2013Leroy C KoppMajor ShareholderBuy9,000$0.39$3,510.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Precipio (NASDAQ PRPO) News Headlines

Source:
DateHeadline
Who Owns Most Of Precipio Inc (NASDAQ:PRPO)?Who Owns Most Of Precipio Inc (NASDAQ:PRPO)?
finance.yahoo.com - May 24 at 4:20 PM
Precipio Launches Liquid Biopsy DNA Enrichment Sales in Europe with First OrderPrecipio Launches Liquid Biopsy DNA Enrichment Sales in Europe with First Order
finance.yahoo.com - May 24 at 9:48 AM
Reviewing Precipio (PRPO) and Bio-Rad Laboratories (BIO)Reviewing Precipio (PRPO) and Bio-Rad Laboratories (BIO)
www.americanbankingnews.com - May 23 at 1:32 PM
Precipio (PRPO) & Agilent Technologies (A) Head-To-Head AnalysisPrecipio (PRPO) & Agilent Technologies (A) Head-To-Head Analysis
www.americanbankingnews.com - May 23 at 9:26 AM
Potential Sequential Revenue Run-Rate Growth of 30% over Q1, based on Preliminary April ResultsPotential Sequential Revenue Run-Rate Growth of 30% over Q1, based on Preliminary April Results
finance.yahoo.com - May 22 at 9:26 AM
Today’s Research Reports on Stocks to Watch: Precipio and Teva PharmaceuticalToday’s Research Reports on Stocks to Watch: Precipio and Teva Pharmaceutical
finance.yahoo.com - May 15 at 10:17 AM
Precipio Shares Run on Increased Sales in Q1Precipio Shares Run on Increased Sales in Q1
www.baystreet.ca - May 14 at 4:17 PM
Precipio Announces Preliminary Q1 2018 Year-over-Year Revenue Increase of 286%Precipio Announces Preliminary Q1 2018 Year-over-Year Revenue Increase of 286%
finance.yahoo.com - May 14 at 10:35 AM
Precipio announces preliminary Q1 revenues; shares ahead 24% premarketPrecipio announces preliminary Q1 revenues; shares ahead 24% premarket
seekingalpha.com - May 14 at 9:16 AM
Precipio (PRPO) Upgraded to "Hold" at ValuEnginePrecipio (PRPO) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - May 2 at 7:06 PM
Precipio Completes a $3M Convertible Debt FacilityPrecipio Completes a $3M Convertible Debt Facility
finance.yahoo.com - April 23 at 9:23 AM
Precipio (PRPO) Says Its in Strategic Partnership Discussions for IV-CellPrecipio (PRPO) Says It's in Strategic Partnership Discussions for IV-Cell
www.streetinsider.com - April 19 at 9:43 AM
Precipio Launches ICE COLD-PCR™ Research Access Program for Cancer CentersPrecipio Launches ICE COLD-PCR™ Research Access Program for Cancer Centers
finance.yahoo.com - April 11 at 10:22 AM
Precipio Inc (NASDAQ:PRPO): Time For A Financial Health CheckPrecipio Inc (NASDAQ:PRPO): Time For A Financial Health Check
finance.yahoo.com - April 10 at 4:17 PM
Technical Perspectives on Medical Research Stocks -- Organovo, PerkinElmer, Precipio, and Thermo Fisher ScientificTechnical Perspectives on Medical Research Stocks -- Organovo, PerkinElmer, Precipio, and Thermo Fisher Scientific
www.bizjournals.com - April 10 at 10:07 AM
Harvard Bioscience (HBIO) versus Precipio (PRPO) Financial ReviewHarvard Bioscience (HBIO) versus Precipio (PRPO) Financial Review
www.americanbankingnews.com - April 8 at 11:23 AM
Head to Head Review: Coherent (COHR) & Precipio (PRPO)Head to Head Review: Coherent (COHR) & Precipio (PRPO)
www.americanbankingnews.com - April 8 at 7:20 AM
Precipio (PRPO) Says JAMA Article Underscores Superiority of its Liquid Biopsy Core TechnologyPrecipio (PRPO) Says JAMA Article Underscores Superiority of its Liquid Biopsy Core Technology
www.streetinsider.com - April 3 at 10:01 AM
Important JAMA Article Underscores Superiority of Precipio’s Liquid Biopsy Core TechnologyImportant JAMA Article Underscores Superiority of Precipio’s Liquid Biopsy Core Technology
finance.yahoo.com - April 3 at 10:01 AM
Precipio Files Patent for Non-Invasive Cell Capture Device For Gynecological Cancer DetectionPrecipio Files Patent for Non-Invasive Cell Capture Device For Gynecological Cancer Detection
finance.yahoo.com - March 28 at 9:56 AM
Precipio enters India liquid biopsy market with adoption by leading laboratory; shares ahead 25% premarketPrecipio enters India liquid biopsy market with adoption by leading laboratory; shares ahead 25% premarket
seekingalpha.com - March 26 at 10:10 AM
Precipio Enters India Liquid Biopsy Market with Adoption by Leading LaboratoryPrecipio Enters India Liquid Biopsy Market with Adoption by Leading Laboratory
finance.yahoo.com - March 26 at 10:10 AM
Precipio Restructures Capitalization TablePrecipio Restructures Capitalization Table
finance.yahoo.com - March 22 at 9:56 AM
Precipio (PRPO) Halted on Second LUDP Following Earlier PRPrecipio (PRPO) Halted on Second LUDP Following Earlier PR
www.streetinsider.com - March 21 at 10:54 AM
Precipio Integrates Cost Reducing and Fast Turnaround "High Resolution Melt" into Liquid Biopsy PlatformPrecipio Integrates Cost Reducing and Fast Turnaround "High Resolution Melt" into Liquid Biopsy Platform
finance.yahoo.com - March 20 at 9:54 AM
Precipio Settles Lawsuit with Crede CapitalPrecipio Settles Lawsuit with Crede Capital
finance.yahoo.com - March 13 at 10:03 AM
Key Measure of Precipio’s Pathology Sales Growth 4X Prior QuarterKey Measure of Precipio’s Pathology Sales Growth 4X Prior Quarter
finance.yahoo.com - February 22 at 9:28 AM
Precipio Launches Unique Lung Cancer Monitoring Test for Therapy ResistancePrecipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance
finance.yahoo.com - February 15 at 8:54 AM
Precipio Announces Q4 2017 Revenue at 350% of Previous QuarterPrecipio Announces Q4 2017 Revenue at 350% of Previous Quarter
finance.yahoo.com - February 9 at 9:04 AM
Precipio Enters Japanese Liquid Biopsy Market with First Hospital SalePrecipio Enters Japanese Liquid Biopsy Market with First Hospital Sale
finance.yahoo.com - February 6 at 8:59 AM
Precipio (PRPO) Upgraded by ValuEngine to "Sell"Precipio (PRPO) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - February 4 at 5:02 PM
Analyzing Precipio (PRPO) and Sunesis Pharmaceuticals (SNSS)Analyzing Precipio (PRPO) and Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - January 28 at 11:12 PM
Reviewing Brainstorm Cell Therapeutics (BCLI) & Precipio (PRPO)Reviewing Brainstorm Cell Therapeutics (BCLI) & Precipio (PRPO)
www.americanbankingnews.com - January 24 at 9:28 PM
Critical Comparison: Precipio (PRPO) versus Its PeersCritical Comparison: Precipio (PRPO) versus Its Peers
www.americanbankingnews.com - January 23 at 5:30 PM
Precipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of PennsylvaniaPrecipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pennsylvania
finance.yahoo.com - January 22 at 5:40 PM
Yale Study Demonstrates Four-Fold Superiority of Academic Level Diagnostic AccuracyYale Study Demonstrates Four-Fold Superiority of Academic Level Diagnostic Accuracy
finance.yahoo.com - January 10 at 9:04 AM
Financial Comparison: Precipio (PRPO) vs. Its CompetitorsFinancial Comparison: Precipio (PRPO) vs. Its Competitors
www.americanbankingnews.com - December 28 at 11:40 AM
Precipio (PRPO) versus Its Competitors Head-To-Head ContrastPrecipio (PRPO) versus Its Competitors Head-To-Head Contrast
www.americanbankingnews.com - December 28 at 5:50 AM
Precipio Launches Its Second New ICE-COLD PCR™ Targeted Enrichment Kit To Identify Mutations in Lung Cancer Using Liquid (Blood) Biopsies On Sanger Sequencing PlatformsPrecipio Launches Its Second New ICE-COLD PCR™ Targeted Enrichment Kit To Identify Mutations in Lung Cancer Using Liquid (Blood) Biopsies On Sanger Sequencing Platforms
finance.yahoo.com - December 20 at 8:58 AM
Precipio Files a Patent Application for IV-Cell, its Novel Cytogenetics Media - GlobeNewswire (press release)Precipio Files a Patent Application for IV-Cell, its Novel Cytogenetics Media - GlobeNewswire (press release)
globenewswire.com - December 16 at 8:59 AM
Precipio Files a Patent Application for IV-Cell, its Novel Cytogenetics MediaPrecipio Files a Patent Application for IV-Cell, its Novel Cytogenetics Media
finance.yahoo.com - December 14 at 9:03 AM
Transgenomic (PRPO) Lifted to Sell at ValuEngineTransgenomic (PRPO) Lifted to Sell at ValuEngine
www.americanbankingnews.com - December 2 at 8:28 PM
Precipio, Inc. :PRPO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Precipio, Inc. :PRPO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 4:21 PM
Precipio, Inc. to Host Earnings CallPrecipio, Inc. to Host Earnings Call
finance.yahoo.com - November 21 at 9:31 AM
Precipio To Announce Third Quarter 2017 Financial Results and Provide a Company Update on Monday, November 20, 2017 at 4:05pm Eastern TimePrecipio To Announce Third Quarter 2017 Financial Results and Provide a Company Update on Monday, November 20, 2017 at 4:05pm Eastern Time
finance.yahoo.com - November 18 at 11:03 AM
Precipio, Inc. Announces Pricing Of $2,748,000 Registered Direct OfferingPrecipio, Inc. Announces Pricing Of $2,748,000 Registered Direct Offering
finance.yahoo.com - November 4 at 9:05 AM
Reviewing Transgenomic (PRPO) and Voyager Therapeutics (VYGR)Reviewing Transgenomic (PRPO) and Voyager Therapeutics (VYGR)
www.americanbankingnews.com - November 4 at 1:20 AM
Precipios ICE-COLD PCR(TM) Technology Selected by Methodist Healthcare System as Their Liquid Biopsy PlatformPrecipio's ICE-COLD PCR(TM) Technology Selected by Methodist Healthcare System as Their Liquid Biopsy Platform
finance.yahoo.com - November 2 at 7:56 AM
Precipios ICE-COLD PCR(TM) Technology Selected by Methodist Healthcare System as Their Liquid Biopsy PlatformPrecipio's ICE-COLD PCR(TM) Technology Selected by Methodist Healthcare System as Their Liquid Biopsy Platform
finance.yahoo.com - November 2 at 7:56 AM
Precipio Announces Completion of Substantial Balance Sheet RestructuringPrecipio Announces Completion of Substantial Balance Sheet Restructuring
finance.yahoo.com - November 2 at 7:56 AM

SEC Filings

Precipio (NASDAQ:PRPO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Precipio (NASDAQ:PRPO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Precipio (NASDAQ PRPO) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.